AIP
PRVL

Ameritas Investment Partners’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Ameritas Investment Partners’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,221
Closed -$28K – 3110
2020
Q4 		$28K Hold
1,221
– – ﹤0.01% 2317
2020
Q3 		$12K Hold
1,221
– – ﹤0.01% 2656
2020
Q2 		$18K Hold
1,221
– – ﹤0.01% 2407
2020
Q1 		$15K Buy
1,221
+605
+98% +$9.63K ﹤0.01% 2357
2019
Q4 		$10K Hold
616
– – ﹤0.01% 2753
2019
Q3 		$8K Buy
+616
New +$6.98K ﹤0.01% 2834

Ameritas Investment Partners's PRVL Position: Q1 2021 in Review

Ameritas Investment Partners sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 1,221 shares — an estimated $28K sold.

Ameritas Investment Partners first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $28K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Ameritas Investment Partners reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 1,221 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $28K.
  • Ameritas Investment Partners first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • Ameritas Investment Partners's Prevail Therapeutics Inc. Common Stock position peaked at $28K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Ameritas Investment Partners's 13F filing for Q1 2021, filed 14 May 2021.